Eisai Celebrates New State-of-the-Art Manufacturing Facility in Baltimore

BALTIMORE, MD, Sept. 12, 2025 – Eisai Inc., the U.S. pharmaceutical headquarters of the Eisai Group of companies, celebrated the grand opening of its new 40,080 square foot Baltimore manufacturing facility on Friday, September 12, 2025. The ribbon-cutting was not only a celebration of the opening, but an opportunity to recognize and congratulate the team on receiving regulatory site approvals from the Food and Drug Administration (FDA), the EU’s European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This site is the only location in the world that manufactures and distributes a specialized implantable wafer used in research studies across the country as well as for the treatment of glioblastoma multiforme, a rare form of brain cancer. This site replaces Eisai’s former manufacturing facility just 20 minutes away.

“I am deeply proud of the efforts made to bring the vision of Eisai’s new Baltimore Manufacturing site to life,” said Tatsuyuki Yasuno, Chairman and CEO of Eisai Inc. “This building is a symbol of our unwavering commitment to patients, innovation and our human health care mission. The dedication of our Baltimore team, who has worked tirelessly and through numerous challenges, is truly inspiring, and their expertise ensures that patients around the world continue to receive a treatment that can make a meaningful difference. We are honored to continue our legacy in Maryland, and proud to invest in the future of U.S. manufacturing.”

“This facility is more than a building—it’s a reflection of the heart and grit of our Baltimore team,” said Trudy Burke, Baltimore Site Head. “For more than 17 years, Eisai has been part of the Maryland community, and today we celebrate a new chapter in that legacy. I’m incredibly proud of our team, who managed the complexities of building a new site, navigating rigorous regulatory reviews, and maintaining a steady global supply of product—all while continuing to operate our former facility and facing the challenges of a global pandemic. Their focus and determination made this possible, and thanks to them, more than 2,000 patients around the world each year will continue to receive a treatment that can make a real difference.”

The ribbon cutting ceremony was attended by Eisai employees along with special guests, including:

• Dr. Henry Brem of Johns Hopkins, co-inventor of the product manufactured at the site,
• a patient advocate and glioblastoma survivor,
• Maryland State Delegate, Kathy Szeliga, and
• Baltimore County District 5 Councilman, David Marks.

“Eisai has done a great public service for patients with glioblastoma. It’s an astounding feeling knowing we’ve done something not only for my patients, but for patients all over the world whom we’ll never meet,” Dr. Henry Brem said. “I congratulate Eisai for their vision and philanthropy. I couldn’t be prouder that this facility is right in our backyard here in Baltimore, supplying the world with this treatment.”

Though Eisai has been part of the Maryland community for more than 17 years, many employees there have manufactured the same product for almost 30 years. Because the wafer is made by hand, the employees’ expertise and experience are essential both to the production of this treatment and to the patients who depend on it. So, in selecting a site for this new facility, Eisai felt it important to remain in the same general area of Maryland, as a commitment to the employees and the patients they serve. Eisai’s investment in this new facility underscores the company’s deep commitment to both the state of Maryland and to U.S. manufacturing. Without this site, the continued availability of this critical medicine would likely not be possible.